Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab

Trial Details

NCT ID
NCT05652673
Phase
NA
Sponsor
Erasmus Medical Center
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • nivolumab
Locations (sample)
  • Rotterdam, Netherlands|51.9225,4.47917

Key Eligibility Criteria

  • 18 years of age or older
  • Irresectable stage III or metastatic melanoma
  • Treated with at least one dose of first-line ipilimumab-nivolumab and considered to be a candidate for maintenance treatment with nivolumab:
  • previous systemic treatment, including immune-checkpoint inhibitors, in (neo)adjuvant setting for resectable melanoma is allowed

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →